Myopathy associated with chronic orlistat consumption: a case report.
The pathogenesis of myopathy due to HMG-CoA reductase inhibitors is not entirely clear but the existence of myopathy due to other lipid-lowering medications suggests it is mediated through effects on lipid metabolism. We describe a patient who developed a myopathy after 27 months of ingestion of orlistat that slowly improved after discontinuation of the drug. Orlistat may have caused this myopathy through depletion of a critical nutrient or through some as of yet undefined mechanism.
Ringman
John M
JM
Alzheimer Disease Research Center, UCLA Department of Neurology, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095-7226, USA. jringman@mednet.ucla.edu <jringman@mednet.ucla.edu>
Mozaffar
Tahseen
T
D000328:Adult; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D009135:Muscular Diseases / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D000077403:Orlistat; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use
D019440:Anti-Obesity Agents; D007783:Lactones; D014451:Ubiquinone; D000077403:Orlistat; D003402:Creatine Kinase; C024989:coenzyme Q10